The CEO of Alphatec Holdings, Miles Patrick, took a path many insiders tread-selling a hundred thousand shares on a Monday, pocketing a cool $2.1 million. The SEC’s paperwork paints a picture of a man who knows when to let go, even if the stock’s story is just heating up. The sale was like a whisper-no thunder, a nod to routine more than revelation.
even giants trim their sails when the wind shifts.
Key questions
- How big was this move in Patrick’s pattern?
If you’ve seen one sale, you’ve seen them all. This one matches the median-neither a leap nor a lull-just a steady hand guiding the ship, typical since late last year. No red flags, just routine contours in a rising tide. - What did it do to the insider’s grip?
He handed over 6.82% of his direct stake, now holding 5.14 million shares. Plenty left for him to hum along with the company’s rhythm. Indirect holdings? Still there-hidden behind a trust, a shell, whatever they call it-same old, same old. - Does this sale signal a shift or just a shuffle?
A cadence as predictable as the city’s heartbeat. 100,000 shares monthly, maybe. Diminishing holdings – about a fifth lost in a year – tightening the noose on further sales. The move looks like a normalization, not a retreat. - And the price-what’s it tell us?
Sold at $21.01, near the day’s close of $21.20. The stock’s been a darling-up 126.3%-selling into strength. The numbers whisper that Patrick knew the swing was high, and he took his cut while the getting was good.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $728.02 million |
| Net income (TTM) | ($154.96 million) |
| Price (as of Monday) | $21.01 |
| 1-year price change | 126.3% |
Company snapshot
- Alphatec’s wheelhouse is spinal surgery. They make devices-neural monitors, implants, biologics-the kind that keep surgeons busy and patients hopeful.
- Revenue streams flow from hospitals and surgical centers, sold through a direct sales crew and a maze of distributors. Big dollars for a company that dances on the cutting edge of spine tech.
- They serve the surgeons, treat the degenerative and the tangled. Their portfolio’s a catalog of hope-rigid, reliable, advanced.
In the world of medical devices, Alphatec’s a player with a steady hand, pushing the boundaries while insiders shuffle the deck. The recent sale? Just another move in a game where everyone’s watching the scoreboard. That the CEO still owns a mountain of shares means the line between him and shareholders isn’t broken-yet. Long-term investors can breathe. The story is still being written, and the money keeps flowing. As for the move itself? A quiet trim, a routine echo of confidence-nothing more, nothing less. When insiders step out of the spotlight, it’s often a sign they see the stage clearly, not the curtain falling 🎯.
Read More
- Spotting the Loops in Autonomous Systems
- Seeing Through the Lies: A New Approach to Detecting Image Forgeries
- The Best Directors of 2025
- Staying Ahead of the Fakes: A New Approach to Detecting AI-Generated Images
- 20 Best TV Shows Featuring All-White Casts You Should See
- The Glitch in the Machine: Spotting AI-Generated Images Beyond the Obvious
- Umamusume: Gold Ship build guide
- Gold Rate Forecast
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Mel Gibson, 69, and Rosalind Ross, 35, Call It Quits After Nearly a Decade: “It’s Sad To End This Chapter in our Lives”
2026-01-11 21:43